公开(公告)号：US11007194B2

公开(公告)日：2021-05-18

申请号：US14355903

申请日：2012-11-09

Applicant: Array BioPharma Inc.

Inventor： Darrin Stuart ,  Meghna Das Thakur

IPC: A61K31/506

Abstract: The present invention relates to a method of treating a patient with a serine/threonine kinase inhibitor wherein resistance to the treatment with a serine/threonine kinase inhibitor is suppressed by administering the serine/threonine kinase inhibitor on an intermittent dosing schedule.

公开(公告)号：US20200246338A1

公开(公告)日：2020-08-06

申请号：US16722384

申请日：2019-12-20

Applicant: Array BioPharma Inc.

Inventor： Giordano Caponigro ,  Darrin Stuart ,  Laure De Parseval

IPC: A61K31/506 ,  A61K45/06 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48 ,  C12Q1/6886

Abstract: Reversing resistance to a B-Raf inhibitor for the treatment of a proliferative disease by obtaining a tumor sample from the patient and testing it for genetic alterations in a panel of genes comprising BRAF, CRAF, CCND1, CDK4, HER2, IGF-1R, cMET, FGFR1, FGFR2, FGFR3, EGFR, MAP2K1, MAP2K2, NRAS, KRAS, HRAS, PTEN, PIK3CA, and P16 and administering a drug combination therapy comprising the B-Raf inhibitor and a second inhibitor which overcomes resistance to the B-Raf inhibitor, which second inhibitor is selected based on genetic alterations discovered in the tumor sample.

公开(公告)号：US10548894B2

公开(公告)日：2020-02-04

申请号：US15875031

申请日：2018-01-19

Applicant: Array BioPharma Inc.

Inventor： Giordano Caponigro ,  Darrin Stuart ,  Laure De Parseval

IPC: A61K31/506 ,  A61K45/06 ,  A61K31/4184 ,  A61K31/4439 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/519 ,  A61K31/53 ,  A61K31/5377 ,  A61K9/00 ,  A61K9/20 ,  A61K9/48 ,  C12Q1/6886

Abstract: Reversing resistance to a B-Raf inhibitor for the treatment of a proliferative disease by obtaining a tumor sample from the patient and testing it for genetic alterations in a panel of genes comprising BRAF, CRAF, CCND1, CDK4, HER2, IGF-1R, cMET, FGFR1, FGFR2, FGFR3 EGFR, MAP2K1, MAP2K2, NRAS, KRAS HRAS, PTEN, PIK3CA, and P16 and administering a drug combination therapy comprising the B-Raf inhibitor and a second inhibitor which overcomes resistance to the B-Raf inhibitor, which second inhibitor is selected based on genetic alterations discovered in the tumor sample.